Publications

June 2012
Case

GlaxoSmithKline in Brazil: Public-Private Vaccine Partnerships

By: Arthur A. Daemmrich and Ian McKown Cornell

Three years into a major public-private partnership between GlaxoSmithKline and Fiocuz, Brazil's principal health institute, the company assesses technology transfer and joint research under the agreement. GSK was selling its Synflorix vaccine (against pediatric... View Details

Keywords: Public-Private Partnerships; Business and Government Relations; Foreign Direct Investment; Health Care and Treatment; Globalized Firms and Management; Pharmaceutical Industry; Pharmaceutical Industry; Brazil

10 Apr 2014
Research & Ideas

John Kotter’s Plan to Accelerate Your Business

that fuel this new dual system in Accelerate: Building Strategic Agility for a Faster-Moving World, released this week. The book is Kotter's latest to address large-scale organizational change. Fifteen years ago, in Leading Change, Kotter offered eight steps View Details

Keywords: by Kim Girard

25 Feb 2014
First Look

First Look: February 25

Abstract—Researchers have long hypothesized that research outputs from government, university, and private company R&D contribute to economic growth, but these contributions may be difficult to measure when they take a non-pecuniary... View Details

Keywords: Sean Silverthorne

16 Oct 2007
First Look

First Look: October 16, 2007

this case: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=508036 Michael Fernandes at Nicholas Piramal Harvard Business School Case 408-001 Michael Fernandes, the Director of Custom Manufacturing Operations at the View Details

Keywords: Sean Silverthorne

01 Jun 2023
News

From Big Pharma to Startup

Hunter Goble (MBA 2022) did not enroll in Harvard Business School with dreams of becoming an entrepreneur. After earning his MBA, Goble intended to return to Eli Lilly to continue to work building brands and launching products. He envisioned himself leading a big,... View Details

Keywords: April White

Web

Industry Information - Alumni

and user-generated content on companies and career issues. HBS alumni version available via eBaker. Covers information on case interviewing, a description of the industry, and profiles of the top 50 consulting firms. McKinsey Quarterly As... View Details

01 Feb 1999
News

Too Much of a Good Thing?

layoffs and lost revenues, for example - weak companies are artificially supported," he explains. "Other firms won't or can't restructure themselves or exit unprofitable businesses because they are too set in their ways, lack sound... View Details

Keywords: Garry Emmons

April 2022
Teaching Note

CVS Health: Prescription for Transformation

By: Rosabeth Moss Kanter and Catarina Martinez

In 2021, new CEO Karen Lynch (named the most powerful woman in business) considered the next transformation phase for CVS Health (a Fortune 5 corporate giant). The 2018 acquisition of Aetna insurance brought her to the company as part of its long evolution from a... View Details

Keywords: Health; COVID-19 Pandemic; Primary Care; Leadership; Change Management; Women Executives; Retail; Pharmacy; Pharmacy Benefit Manager; Clinical Trials; Vaccination; Acquisition; Innovation and Invention; Transformation; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States

22 Nov 2004
Research & Ideas

Side Effects: The Case of Propecia

"staggering" 90 percent brand awareness, she said. The problem: some of that awareness was driven by the much-publicized side effects issue. It was difficult for the drug maker to convey the true risk information necessary to blunt the side effects buzz. The... View Details

Keywords: by Sean Silverthorne; Pharmaceutical; Pharmaceutical

18 Nov 2014
First Look

First Look: November 18

were the strengths and challenges facing this model? How would the model evolve in the future? And how would new, similar collaboration models surfacing at other major pharmaceutical companies pose a threat... View Details

Keywords: Sean Silverthorne

July 2016 (Revised July 2019)
Teaching Plan

Doctor My Eyes: The Acquisition of Bausch & Lomb by Warburg Pincus (A)

By: Nori Gerardo Lietz and Ricardo Andrade

In early 2010, senior partners at Warburg Pincus met to review a report on Bausch & Lomb Incorporated, the firm's largest investment at the time. Warburg Pincus had led a group of investors in acquiring Bauch & Lomb on October 26, 2007, taking the company private and... View Details

Keywords: Health Care; Mergers ＆ Acquisitions; Governance; Buyout; Private Equity; Finance; Mergers and Acquisitions; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States

April 2016 (Revised July 2019)
Case

"Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (A)

By: Nori Gerardo Lietz

In early 2010, senior partners at Warburg Pincus met to review a report on Bausch & Lomb Incorporated, the firm's largest investment at the time. Warburg Pincus had led a group of investors in acquiring Bauch & Lomb on October 26, 2007, taking the company private and... View Details

Keywords: Health Care; Mergers ＆ Acquisitions; Governance; Buyout; Private Equity; Finance; Mergers and Acquisitions; Corporate Governance; Health Care and Treatment; Reports; Business Model; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States

07 Feb 2012
First Look

First Look: February 7

company can justify the expense of assembling records. The Internet has transformed how economists interact with these datasets by lowering the cost of storing, updating, distributing, finding, and retrieving this information. Second,... View Details

Keywords: Sean Silverthorne

28 Jul 2008
Research & Ideas

Making the Decision to Franchise (or not)

appears to be true when you get a new type of consumer for the same product." In the pharmaceutical industry, for example, selling medicine to both an independent general practitioner and a hospital will require a different organizational... View Details

Keywords: by Julia Hanna; Retail

February 2009
Case

Avid Radiopharmaceuticals: The Venture Debt Question

By: Matthew Rhodes-Kropf and Ann Leamon

The CEO of a promising biotech company must decide how to respond to the macro-economic slump of late 2008. He had planned to pursue an aggressive schedule, moving the firm's Alzheimer's and Parkinson's disease imaging compounds through clinical trials and into the... View Details

Keywords: Financial Crisis; Entrepreneurship; Borrowing and Debt; Venture Capital; Financial Management; Investment; Health Testing and Trials; Expansion; Pharmaceutical Industry; Pharmaceutical Industry

2024
Working Paper

Dusting Off the Old Ones: Drug Licensing to Startups, Innovation Success and Efficiency

By: Mosab Hammoudeh, Joshua Lev Krieger and Jiajie Xu

This paper investigates whether moving R&D from incumbents to startups can increase innovation. Using comprehensive drug development data, we examine the outcomes of drug projects licensed from large firms to startups. We find that these projects licensed to startups... View Details

Keywords: Product Development; Innovation and Invention; Business Startups; Research and Development; Performance Efficiency; Pharmaceutical Industry